# Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

> **NCT04875169** · PHASE3 · COMPLETED · sponsor: **Reistone Biopharma Company Limited** · enrollment: 336 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Core Treatment Active Experimental: SHR0302 Dose#1
- **DRUG:** Core Treatment Active Experimental: SHR0302 Dose#2
- **DRUG:** Core Treatment Placebo Comparator: Placebo
- **DRUG:** Extension Treatment Active Experimental: SHR0302 Dose#1
- **DRUG:** Extension Treatment Active Experimental: SHR0302 Dose#2

## Key facts

- **NCT ID:** NCT04875169
- **Lead sponsor:** Reistone Biopharma Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-30
- **Primary completion:** 2022-08-12
- **Final completion:** 2023-05-23
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04875169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04875169, "Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04875169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*